UTRS (Minerva Surgical) DeferredTaxAndRevenue: $0.20 Mil (As of Sep. 2023)


What is Minerva Surgical DeferredTaxAndRevenue?

Minerva Surgical UTRS -99.00% DeferredTaxAndRevenue is $0.20 Mil as of Sep. 2023.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Minerva Surgical's current deferred tax and revenue for the quarter that ended in Sep. 2023 was $0.20 Mil.

Minerva Surgical DeferredTaxAndRevenue Related Terms

Minerva Surgical DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Minerva Surgical's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minerva Surgical DeferredTaxAndRevenue Chart

Minerva Surgical Annual Data
Trend Dec19 Dec20 Dec21 Dec22
DeferredTaxAndRevenue
0.38 0.66 0.48 0.34

Minerva Surgical Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.36 0.34 0.58 0.25 0.20
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of $0.20 Mil mean?
Minerva Surgical (UTRS) has a DeferredTaxAndRevenue of $0.20 Mil as of Sep. 2023. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Minerva Surgical.
Is Minerva Surgical's DeferredTaxAndRevenue too high?
Minerva Surgical's current DeferredTaxAndRevenue is $0.20 Mil.
How does Minerva Surgical's DeferredTaxAndRevenue compare to PAVM and ELUT?
Minerva Surgical's DeferredTaxAndRevenue of $0.20 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Medical Devices & Instruments company?
A good DeferredTaxAndRevenue depends on the Medical Devices & Instruments industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Minerva Surgical. Minerva Surgical's current DeferredTaxAndRevenue is $0.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minerva Surgical stock overvalued right now?
Minerva Surgical (UTRS) has a current DeferredTaxAndRevenue of $0.20 Mil. The current DeferredTaxAndRevenue is $0.20 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Minerva Surgical (UTRS), the current DeferredTaxAndRevenue is $0.20 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Minerva Surgical Business Description

Address 4255 Burton Drive, Santa Clara, CA, USA, 95054
Minerva Surgical Inc is a medical device company that develops therapeutic devices that treat abnormal uterine bleeding in a minimally invasive manner. The Company operates and manages its business as one reportable and operating segment, which is the business of research, development, and sale of therapeutic devices for abnormal uterine bleeding treatment.